Italia markets closed
  • Reuters

    UPDATE 1-U.S. reluctance to lift all sanctions main obstacle to reviving 2015 pact - Iranian official

    The reluctance of the United Sates to lift all sanctions on Iran is the main challenge to reviving the 2015 nuclear pact, a senior Iranian foreign ministry official was cited as saying by Iranian media on Sunday. Indirect talks between Washington and Tehran on reinstating their nuclear pact broke off https://www.reuters.com/world/middle-east/iran-nuclear-talks-break-friday-with-formal-meeting-officials-2021-12-03 on Friday, with both sides saying they would resume the following week, as Western officials voiced dismay at sweeping demands by the Islamic Republic.

  • Reuters

    Swiss watchdog seeks more tools to go after bad bankers - paper

    The chairperson of Switzerland's financial watchdog has called for more power to punish wayward bankers after a string of scandals tarnished the sector's international reputation. Marlene Amstad, head of the Swiss Financial Market Supervisory Authority's (FINMA) board of directors, told the SonntagsZeitung paper the agency would welcome new tools to hold bankers accountable for the mistakes they make. While FINMA can now remove bankers who make grave errors, it lacks the kind of broader toolkit that Britain, for example, has with its Senior Manager Regime, she said in the interview.

  • Motley Fool

    Is Longeveron a Good Biotech Stock to Buy?

    An American biotechnology company located in Miami of all places has convinced more than a few investors that its cellular therapy candidate can reverse common effects of aging. This November, shares of Longeveron (NASDAQ: LGVN) shot up more than 10-fold. Investors who missed the boat the first time around are wondering if Longeveron the recent slide is an opportunity to buy a potential long-term winner at a relative discount.